Finance

Beta
Lists
OMCL:NASDAQ
Omnicell Inc
$43.00
-1.38%
(-0.60) 1D
$43.00
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OMCL...
Open
$43.60
High
$44.53
Low
$42.98
Mkt. cap
1.96B
Avg. vol.
619.61K
Volume
337.28K
P/E ratio
97.47
52-wk high
$55.00
52-wk low
$26.84
EPS
$0.44
Beta
0.97
Shares outstanding
45.48M
No. of employees
4K
Open
$43.60
High
$44.53
Low
$42.98
Mkt. cap
1.96B
Avg. vol.
619.61K
Volume
337.28K
P/E ratio
97.47
52-wk high
$55.00
52-wk low
$26.84
EPS
$0.44
Beta
0.97
Shares outstanding
45.48M
No. of employees
4K
Analyst outlook
Analyst Ratings
Based on 5 analysts giving stock ratings to OMCL in the past 3 months
Strong Buy
Buy
4
Hold
1
Sell
0
12 month forecast
Based on 5 Wall Street analysts offering 12 month price targets for OMCL in the last 3 months.
Highest
Current $43.00
$70.00 (+62.79%)
Average
$62.50 (+45.35%)
Lowest
$55.00 (+27.91%)
News stories
From sources across the web
Profile
Omnicell, Inc. is an American multinational healthcare technology company headquartered in Mountain View, CA. It manufactures automated systems for medication management in hospitals and other healthcare settings, and medication adherence packaging and patient engagement software used by retail pharmacies. Its products are sold under the brand names Omnicell and EnlivenHealth. Wikipedia
About Omnicell Inc
CEORandall A. Lipps
Employees3.52K
FoundedSep 1992
HeadquartersMountain View, California, United States
SectorMedical device
Websiteomnicell.com
Last report
Apr 28, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.55 / $0.33
+66.04%beat
Revenue / Est. (USD)
309.88M / 304.06M
+1.91%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
290.56M
310.63M
313.98M
309.88M
Cost of goods sold
162.88M
176.13M
179.06M
169.52M
Cost of revenue
162.88M
176.13M
179.06M
169.52M
Research and development expenses
21.57M
24.02M
21.62M
21.52M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
97.98M
102.24M
106.39M
101.99M
Operating expense
119.56M
126.26M
128.01M
123.51M
Total operating expenses
282.44M
302.39M
307.06M
293.03M
Operating income
8.12M
8.24M
6.92M
16.85M
Other non operating income
-
-
-
-
EBT including unusual items
10.45M
9.70M
699.00K
16.90M
EBT excluding unusual items
10.45M
9.70M
7.20M
16.90M
Income tax expense
4.81M
4.24M
2.72M
5.55M
Effective tax rate
46.05%
43.71%
389.84%
32.81%
Other operating expenses
-
-
-
-
Net income
5.64M
5.46M
-2.03M
11.36M
Net profit margin
1.94%
1.76%
-0.65%
3.67%
Earnings per share
0.45
0.51
0.40
0.55
Interest and investment income
3.41M
2.48M
1.79M
785.00K
Interest expense
-1.08M
-1.02M
-1.51M
-734.00K
Net interest expenses
2.33M
1.46M
284.00K
51.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
22.11M
22.55M
43.13M
30.73M
Gain or loss from assets sale
181.00K
116.00K
80.00K
122.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer